FDA permits marketing of first newborn screening system for detection of four, rare metabolic disorders (FDA - Food and Drug Administration)
(World News Science)

(Source: FDA - Food and Drug Administration) The U.S. Food and Drug Administration today permitted marketing of the Seeker System for the screening of four, rare Lysosomal Storage Disorders (LSDs) in newborns. The Seeker system is designed to detect Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher and Fabry. It is the first newborn screening test permitted to be marketed by the FDA for these disorders. LSDs are a group of rare, inherited metabolic disorders in which enzymes (proteins) that normally eliminate unwanted substances in the body`s cells are not at normal levels or functioning properly. According to the U.S. Department of Health and Human Services` Advisory Committee on...